Drug Trial Radar · NCT02736565
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
Last checked: Nov 20, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Oct 2016
Primary completion
Aug 12, 2019
Study completion Aug 4, 2020
Sponsor
- Lead sponsor
- Gradalis, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 13, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and the maximum tolerated dose of of pbi-shRNA™ EWS/FLI1 Type 1 lipoplex in patients with advanced Ewing's sarcoma.
Conditions
- Ewing's Sarcoma
- Ewing Family of Tumors
- Ewing's Tumor Metastatic
- Ewing's Sarcoma Metastatic
- Ewing's Tumor Recurrent
- Rare Diseases
- Sarcoma
Interventions
pbi-shRNA™ EWS/FLI1 Type 1 LipoplexBiological
Lipoplex is given intravenously as a single administration twice a week for 4 weeks for a total of 8 infusions per cycle followed by 2 weeks of rest. Treatment may continue as long as there is clinical benefit, no evidence of disease progression, and no other withdrawal criteria are met. First dose started on Cycle 1 Week 1 Day 1 followed by observation and safety assessment for 13 days. If no toxicity was observed, then another single administration of study agent was given at Cycle 1 Week 3 Day 1 followed by observation and safety for 6 days. If no toxicity was observed, then study agent was given twice a week on Days 1 and 4 over 3 weeks, for a total of 8 infusions per cycle, followed by a 2-week washout before starting each subsequent cycle. Cycle 1 = 8 weeks. Each subsequent cycles = 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v4.0Time frame: From first dose and up to 60 days following the last treatment, up to approximately 13 months.
- Determine the maximum tolerated dose of intravenous administration of lipoplexTime frame: From first subject, first dose and after an additional 6 subjects have been treated at the MTD, up to 4 weeks.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Memorial Sloan Kettering Cancer Center
New York, New York
Mary Crowley Cancer Research Centers
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.